Blood tests alone cannot diagnose osteoporosis, but they play a critical role in uncovering why bone loss is happening and whether treatment is working. A standard workup typically includes serum calcium, phosphate, creatinine, alkaline phosphatase, 25-hydroxyvitamin D, parathyroid hormone, a complete blood count, and thyroid-stimulating hormone. Beyond that baseline panel, your doctor may order bone turnover markers, hormone levels, or screening tests for conditions that silently erode bone. The specific combination depends on your age, sex, fracture history, and what the initial results reveal.
The Baseline Panel
When osteoporosis is suspected or confirmed by a bone density scan, clinicians order a set of blood tests aimed at ruling out treatable causes of bone loss. These are not exotic or expensive tests. Most are part of routine metabolic panels you may have had before, just interpreted with bone health in mind. A standard baseline workup includes serum calcium, phosphate, creatinine, alkaline phosphatase, and 25-hydroxyvitamin D, with testosterone added for men.1PubMed Central. Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis Most guidelines also call for parathyroid hormone, a full blood count, and thyroid-stimulating hormone as part of the initial screen.2Europe PMC. Secondary osteoporosis
Each of these tests tells a different part of the story. Calcium and phosphate levels reflect mineral balance. Creatinine flags kidney problems that can throw off calcium handling. Alkaline phosphatase is an enzyme partly made by bone-forming cells, and a high level can signal unusually rapid bone turnover or liver disease. A full blood count can reveal anemia or abnormal cell populations that hint at blood cancers like myeloma. And thyroid-stimulating hormone helps catch an overactive thyroid, which is a well-known driver of bone loss.
Vitamin D and Parathyroid Hormone
Vitamin D gets its own spotlight because deficiency is remarkably common in people with osteoporosis and directly impairs calcium absorption. The test measures 25-hydroxyvitamin D, the circulating form your liver produces. Low levels don’t just correlate with weaker bones; they also trigger a rise in parathyroid hormone, which pulls calcium out of bone to keep blood levels stable. That chain reaction is why these two tests are almost always ordered together. Low calcium intake and vitamin D deficiency appear positively correlated with the prevalence of osteoporosis, though neither vitamin D levels nor calcium intake alone are enough to diagnose the condition.3PubMed Central. Vitamin D and Calcium in Osteoporosis, and the Role of Bone Turnover Markers: A Narrative Review of Recent Data from RCTs
When parathyroid hormone comes back elevated alongside normal or low calcium, primary hyperparathyroidism is on the table. That’s a condition where one or more parathyroid glands are overactive, steadily dissolving bone to maintain blood calcium. It’s surgically curable, which makes catching it through a routine blood draw particularly valuable. If both calcium and parathyroid hormone are high, the diagnosis is fairly straightforward. If only parathyroid hormone is elevated and calcium is low, the more likely explanation is vitamin D deficiency driving compensatory hormone production.
Bone Turnover Markers
Bone is constantly being broken down and rebuilt. Bone turnover markers are proteins or protein fragments released during that remodeling process, and measuring them gives a snapshot of how fast your skeleton is changing right now. The two reference markers endorsed by expert consensus are CTX for bone resorption and PINP for bone formation.4PubMed Central. The Role of PINP in Diagnosis and Management of Metabolic Bone Disease
CTX, short for C-terminal telopeptide of type I collagen, is a fragment released when bone is broken down. It’s considered the best resorption marker because it’s a direct byproduct of bone digestion, giving clinicians a real-time look at how quickly bone is being lost.5PubMed Central. The Treatment and Monitoring of Osteoporosis using Bone Turnover Markers PINP, or procollagen type I N-propeptide, comes from the opposite side of the equation. It’s shed when new collagen is being laid down to build bone. PINP has some practical advantages in a clinical setting: it doesn’t swing much throughout the day, it isn’t affected by eating, and it stays stable in a blood sample after it’s drawn.4PubMed Central. The Role of PINP in Diagnosis and Management of Metabolic Bone Disease
These markers don’t replace a bone density scan. They can’t tell you how dense your bones are today. What they can do is detect changes in bone activity much sooner than a repeat density scan would. That makes them especially useful for monitoring treatment, which is discussed further below.
Why Timing and Fasting Matter for Bone Markers
If your doctor orders CTX in particular, you’ll likely be told to fast overnight and have your blood drawn early in the morning. That isn’t arbitrary. Bone turnover follows a daily rhythm, peaking in the early morning and dropping significantly by midday. On top of that, eating suppresses resorption markers, so a post-breakfast blood draw can produce misleadingly low CTX values.6Australian Family Physician. Bone turnover markers If you’re getting repeat testing to track how treatment is working, the blood should be drawn at the same time of day each visit. Without that consistency, the results are hard to interpret.
PINP is less sensitive to these fluctuations, which is one reason some clinicians prefer it as a formation marker. But even with PINP, standardized collection conditions reduce noise in the results. If you’ve been given specific instructions about fasting or timing, follow them closely. A single poorly timed sample can look like treatment failure when it’s really just a measurement artifact.
Screening for Secondary Causes
Osteoporosis isn’t always a standalone condition. In many cases, another disease or medication is driving the bone loss. When the baseline panel hints at something deeper, or when osteoporosis shows up in someone younger than expected, clinicians expand the testing to hunt for secondary causes. A standardized workup at one osteoporosis center included a comprehensive metabolic panel, 25-hydroxyvitamin D, parathyroid hormone, thyroid testing, a complete blood count, phosphorus, celiac screening, and 24-hour urine calcium.7Journal of the Endocrine Society. THU422 Laboratory Evaluation For Etiologies Of Secondary Osteoporosis
The range of possible culprits is wide, and the blood tests ordered reflect that breadth.
Thyroid Disease
An overactive thyroid speeds up bone turnover, and the bone loss can be substantial. Untreated severe hyperthyroidism increases the probability of high-turnover osteoporosis. Even subclinical hyperthyroidism, where thyroid-stimulating hormone is low but the thyroid hormones themselves remain in the normal range, can decrease bone density and raise fracture risk, particularly in postmenopausal women.8Europe PMC. Thyroid Hormone Diseases and Osteoporosis This is why thyroid-stimulating hormone is included in the baseline panel even for patients who have no obvious thyroid symptoms.
Celiac Disease
Celiac disease damages the lining of the small intestine and can impair absorption of calcium and vitamin D, leading to bone loss. The screening test is an IgA anti-tissue transglutaminase antibody, which can be done on a standard blood draw. In one study of 460 patients with osteoporosis, roughly 1% tested positive for celiac disease by both serology and biopsy.9PMC (PubMed Central). Is it necessary to screen for celiac disease in adult idiopathic osteoporosis? One percent may sound low, but celiac is a condition where a relatively simple dietary change (going gluten-free) can halt the damage and let bones recover. Missing it means treating the osteoporosis while the underlying cause quietly persists.
Multiple Myeloma
Myeloma is a blood cancer that produces abnormal proteins and eats away at bone. It can mimic osteoporosis on a density scan, and some cases are first suspected only because a patient presented with unexplained bone loss. Serum protein electrophoresis is used to look for a monoclonal band, an abnormal spike of a single protein type. In a study of patients referred for bone density testing, about 5% of those with osteoporosis had a monoclonal component in their serum, and three of those patients were ultimately diagnosed with multiple myeloma. Monoclonal gammopathy of undetermined significance, a precursor condition worth monitoring, was found in about 4% of the osteoporosis group.10Europe PMC. Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: retrospective, cross sectional study Not every osteoporosis patient gets this test, but it’s commonly ordered when the clinical picture doesn’t quite fit standard postmenopausal or age-related bone loss.
Excess Cortisol
Too much cortisol, whether from Cushing’s disease, adrenal tumors, or long-term steroid medication, attacks bone with unusual speed. Cortisol suppresses bone formation while ramping up resorption, and the resulting osteoporosis can be severe. When Cushing’s is suspected, the typical screening tests include a 24-hour urine free cortisol, midnight salivary cortisol, and a low-dose dexamethasone suppression test, which measures whether the body’s cortisol production shuts down appropriately in response to an external dose. In one reported case, a patient with accelerated osteoporosis had urine free cortisol levels of 190 and 132 micrograms, far above the normal upper limit of 45, and midnight salivary cortisol levels of 160 and 513 nanograms per deciliter against a normal cutoff of 100.11Journal of the Endocrine Society. SAT-266 Accelerated Osteoporosis – a Rare Presentation of Cushing’s Disease These tests are not part of every osteoporosis workup, but they become essential when bone loss is rapid, unexplained, or accompanied by other signs of cortisol excess like weight gain, thin skin, or easy bruising.
Kidney Function and Treatment Safety
Creatinine shows up in the baseline panel for two reasons. First, kidneys play a central role in activating vitamin D and regulating calcium. Impaired kidney function can produce a chemical picture that looks like other causes of bone loss but requires completely different management. Second, the most commonly prescribed osteoporosis medications, bisphosphonates, are cleared through the kidneys. In patients with significantly reduced kidney function, bisphosphonate therapy can actually backfire. A meta-analysis found that in patients with moderately to severely reduced kidney function (stage G3B chronic kidney disease), one bisphosphonate increased fracture risk rather than reducing it.12PubMed Central. The Efficacy and Safety of Bisphosphonate Therapy for Osteopenia/Osteoporosis in Patients With Chronic Kidney Disease: A Systematic Review and Individual Patient-Level Meta-Analysis of Placebo-Controlled Randomized Trials Knowing your kidney function before starting treatment isn’t optional; it determines which drugs are safe for you.
Kidney disease also affects how bone turnover markers should be interpreted. Some fragments that serve as bone breakdown markers are cleared by the kidneys, so reduced kidney function can artificially inflate their levels. Your doctor has to account for this when reading the results, which is one more reason creatinine is checked upfront.
24-Hour Urine Calcium
This isn’t a blood test, but it’s frequently ordered alongside the blood work and worth understanding in context. A 24-hour urine collection measures how much calcium your kidneys are dumping. Too much calcium in the urine (hypercalciuria) can indicate a leak that’s draining your skeleton. Too little (hypocalciuria) might point to poor calcium absorption from the gut or inadequate intake. In one large osteoporosis center study, among patients who completed the collection, about a quarter had hypercalciuria and a similar proportion had hypocalciuria.7Journal of the Endocrine Society. THU422 Laboratory Evaluation For Etiologies Of Secondary Osteoporosis
The practical problem is compliance. The same study found that fewer than half of patients actually completed the urine collection, even when it was a standard part of the protocol.7Journal of the Endocrine Society. THU422 Laboratory Evaluation For Etiologies Of Secondary Osteoporosis Collecting every drop of urine for a full day is genuinely inconvenient, and some patients simply don’t do it. That’s unfortunate, because the results can change management: a patient with hypercalciuria might benefit from a thiazide diuretic that reduces calcium loss through the kidneys, while one with hypocalciuria might need a closer look at their gut absorption or dietary intake.
Inflammatory Markers
Chronic inflammation can accelerate bone loss, and in certain patient populations, markers like C-reactive protein and erythrocyte sedimentation rate become relevant. These are not standard in every osteoporosis workup, but they matter when an inflammatory condition is suspected. In patients with ankylosing spondylitis, for example, those with osteoporosis had significantly higher CRP and sedimentation rates than those without osteoporosis.13PubMed Central. The relation between osteoporosis and vitamin D levels and disease activity in ankylosing spondylitis Rheumatoid arthritis, inflammatory bowel disease, and other chronic inflammatory conditions can all contribute to bone loss through similar pathways. If you have one of these conditions and are being evaluated for osteoporosis, expect inflammatory markers to show up on your lab order.
Monitoring Treatment With Blood Tests
Once you start osteoporosis treatment, blood tests shift from diagnostic to monitoring tools. A bone density scan takes one to two years to show a meaningful change. Bone turnover markers can reflect a treatment response within three to six months, which gives your doctor a much earlier signal about whether the medication is working.
Expert consensus supports using CTX and PINP as short-term monitoring tools to assess responses to osteoporosis therapy and adjust treatment earlier than bone density scanning would allow. Either the absolute values or the degree of change from a pre-treatment baseline can be used to gauge how well a medication is performing.14PubMed. Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region The practical implication is straightforward: if you start a drug that’s supposed to slow bone breakdown, your CTX should drop. If you’re on a bone-building drug, your PINP should rise. If neither happens within the expected window, the treatment plan may need revisiting.
These markers have also been incorporated into fracture liaison services, which are programs designed to catch people who’ve already broken a bone and get them into treatment. Tracking marker changes helps keep patients engaged. Seeing a measurable response in a blood test can be motivating in a way that “come back in two years for another scan” is not.
Sex Hormones
Estrogen and testosterone both protect bone, and low levels of either are established drivers of osteoporosis. In women, menopause is the most common trigger, and estrogen levels are not typically measured because the diagnosis is clinically obvious. In men, however, testosterone deficiency can be subtle and easily missed. Current recommendations include testing testosterone as part of the baseline workup in men with osteoporosis.1PubMed Central. Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis Low testosterone in men doesn’t just contribute to bone loss; it also reduces muscle mass and increases fall risk, compounding the fracture problem from two directions.
In premenopausal women with unexplained osteoporosis, hormone testing may also be warranted. Conditions like premature ovarian insufficiency or hypothalamic amenorrhea (where periods stop due to low body weight, excessive exercise, or stress) can produce bone loss years before menopause would normally occur. If your doctor suspects one of these, expect estradiol and follicle-stimulating hormone to be ordered.
Emerging Markers
Research is exploring whether newer blood markers can improve osteoporosis detection. Sclerostin, a protein made by bone cells that acts as a brake on bone formation, has attracted attention as a potential diagnostic marker. In one study, sclerostin levels were significantly lower in people with osteoporosis and osteopenia compared to controls, and a cutoff of 5.6 nanograms per milliliter showed good sensitivity and specificity for identifying osteoporosis.15Europe PMC. Serum sclerostin levels as a diagnostic marker for osteoporosis The finding is interesting because it represents a different axis of bone biology than traditional turnover markers, reflecting regulation of the bone-building pathway rather than byproducts of breakdown or formation.
Sclerostin is not yet part of standard clinical practice for osteoporosis diagnosis, and the evidence base remains thin compared to established markers like CTX and PINP. But it has an indirect clinical footprint already: romosozumab, one of the newer osteoporosis drugs, works by blocking sclerostin. As that drug sees wider use, interest in measuring its target will likely grow. For now, though, sclerostin testing lives firmly in the research space. If you see it on a lab order, you’re probably enrolled in a study or seeing a specialist with a particular interest in bone metabolism.